SCHEMBL18201811

SCHEMBL18201811

CC(C)(C)OC(=O)N1CC2(CN(Cc3ccc(N)nc3)C2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.49
ALOX5AP P20292 1/20 0.42
FEN1 P39748 1/20 0.42
GPR119 Q8TDV5 6/20 0.41
PIK3CA P42336 2/20 0.41
MTOR P42345 2/20 0.41
PARP1 P09874 1/20 0.39
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
GHSR Q92847 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18201816 0.90 PIK3CA (0.44) RORCALOX5APFEN1PIK3CAMTOR
SCHEMBL29686670 0.90 PIK3CA (0.44) RORCALOX5APFEN1PIK3CAMTOR
SCHEMBL20528288 0.90 CYP1A2 (0.47) RORCPIK3CAMTOROPRD1OPRK1
SCHEMBL29687028 0.90 RORC (0.42) RORCALOX5APFEN1GPR119PIK3CA
SCHEMBL18201923 0.90 RORC (0.42) RORCALOX5APFEN1GPR119PIK3CA
SCHEMBL30584532 0.85 MEN1 (0.49) GPR119TBK1
SCHEMBL1997213 0.85 MEN1 (0.49) GPR119TBK1
SCHEMBL18201812 0.84 CYP3A4 (0.48) GPR119PIK3CAMTOROPRD1OPRK1
SCHEMBL16891998 0.82 RORC (0.47) RORCGPR119PARP1OPRD1OPRK1
SCHEMBL25327050 0.82 RORC (0.50) RORCGPR119PARP1GHSRTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288931-B2 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2022-07-20 EP disclosed
EP-3288931-B1 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2019-11-06 EP disclosed
US-10450316-B2 Certain protein kinase inhibitor Chongqing Fochon Pharmaceutical Co., Ltd. (CN) 2019-10-22 US disclosed
US-20180291027-A1 CERTAIN PROTEIN KINASE INHIBITOR FOCHON BIOSCIENCES, LTD. (CN) 2018-10-11 US disclosed
WO-2016173505-A1 CERTAIN PROTEIN KINASE INHIBITOR SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2016-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450316-B2 Certain protein kinase inhibitor CDK4, CDK6, CDK2 RORC 1539/4885ALOX5AP 3099/4885FEN1 1385/4885
US-20180291027-A1 CERTAIN PROTEIN KINASE INHIBITOR CDK4, CDK6, CDK2 RORC 2021/4885ALOX5AP 3483/4885FEN1 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.